Behavioral health personalized medicine company AssureRx Health has secured an $8 million line of credit as it looks to boost adoption of its genetic screening test for psychiatric drugs.Along with an $11 million series B round of funding that the company obtained last year, the line of credit will help fund the development of several [...]

Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs.The illumigene Mycoplasma test is currently in clinical trials, according to a statement from Meridian announcing the Cincinnati-area company’s first-quarter earnings. Meridian plans to launch three to four new illumigene tests per year, [...]

Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs.The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to [...]

Looming cuts to low-income healthcare assistance program Medicaid are creating budgeting challenges for administrators at Cincinnati Children’s Hospital Medical Center.The hospital’s $1.7 billion budget will remain flat this year and Cincinnati Children’s plan to keep its employee count steady at around 12,650 workers, the Cincinnati Enquirer reported. Cincinnati Children’s budget will stay flat despite an [...]

Cardiac device company AtriCure (NASDAQ:ATRC) has again been identified by an equities analyst as a likely acquisition target for a big medical device firm.Barrington Research listed Cincinnati-area AtriCure as among its top 15 stock picks for the year and called the company a strong candidate for a buyout, the Cincinnati Business Courier reported.“ATRC has the [...]

Akebia Therapeutics has spun off a new company, the similarly named Aerpio Therapeutics, to develop drugs for diabetic macular edema and inflammatory bowel disease.Akebia will continue developing its oral anemia drug candidate, according to a statement from the Cincinnati-area company.var page_count = “off”; if (typeof [...]

Diagnostic test maker Meridian Bioscience‘s (NYSE:VIVO) Chief Executive Jack Kraeutler received a 3 percent increase in compensation this year to $843,000.Here’s how Kraeutler’s 2011 compensation breaks down, according to a recent regulatory filing: $546,000 in base salary; $228,000 in stock awards and $69,000 in “other” compensation, which includes retirement contributions, auto allowance and financial planning.Unlike [...]

Meridian Bioscience Inc. (NASDAQ: VIVO), the Cincinnati, Ohio diagnostic test maker, has received FDA clearance for its new Clostridium difficile test.The ImmunoCard C. difficile GDH test has already been launched in global markets for screening of the bacteria, a common hospital-acquired infection. Toxigenic strains of C. difficile cause diarrhea and can lead to life-threatening complications [...]

Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received regulatory clearance of a molecular diagnostics test for group B streptococcus.The group B strep test is the second in the Cincinnati-area company’s illumigene line of molecular diagnostic tests to be cleared by the U.S. Food and Drug Administration. The illumigene product line is key to Meridian’s future [...]

A startup that’s hoping to be the first to commercialize a blood test that can diagnose the cause of stroke has received a state loan for nearly $1 million.The $943,000 in financing for Cincinnati-area IschemiaCare comes through the Innovation Ohio Loan Fund program, which is aimed at helping companies in the state develop “next-generation” products.IschemiaCare‘s [...]